GeorgeMMNewMITenSSultanCBhangooA. The clinical and molecular heterogeneity of 17βHSD-3 enzyme deficiency. Horm Res Paediatr. 2010;74(4):229-240. doi:10.1159/000318004.
2.
MendoncaBBGomesNLCostaEM, et al. 46, XY disorder of sex development (DSD) due to 17β-hydroxysteroid dehydrogenase type 3 deficiency. J Steroid Biochem Mol Biol. 2017;165(pt A):79-85. doi:10.1016/j.jsbmb.2016.05.002.
3.
WisniewskiABBatistaRLCostaEMF, et al. Management of 46,XY differences/disorders of sex development (DSD) throughout life. Endocr Rev. 2019;40(6):1547-1572. doi:10.1210/er.2019-00049.
4.
AhmedSFBashambooALucas-HeraldAMcElreaveyK. Understanding the genetic aetiology in patients with XY DSD. Br Med Bull. 2013;106:67-89. doi:10.1093/bmb/ldt008.
5.
BerglundAJohannsenTHStochholmK, et al. Incidence, prevalence, diagnostic delay, and clinical presentation of female 46,XY disorders of sex development. J Clin Endocrinol Metab. 2016;101(12):4532-4540. doi:10.1210/jc.2016-2248.
6.
LeePANordenströmAHoukCP, et al. Global disorders of sex development update since 2006: perceptions, approach and care. Horm Res Paediatr. 2016;85(3):158-180. doi:10.1159/000442975.
7.
BoehmerALBrinkmannAOSandkuijlLA, et al. 17Beta-hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics, and worldwide distribution of ancient and de novo mutations. J Clin Endocrinol Metab. 1999;84(12):4713-4721. doi:10.1210/jcem.84.12.6174.
8.
LeeYSKirkJMStanhopeRG, et al. Phenotypic variability in 17beta-hydroxysteroid dehydrogenase-3 deficiency and diagnostic pitfalls. Clin Endocrinol (Oxf). 2007;67(1):20-28. doi:10.1111/j.1365-2265.2007.02829.x.
LeePAHoukCPAhmedSFHughesIA. International Consensus Conference on Intersex organized by the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. Consensus statement on management of intersex disorders. International Consensus Conference on Intersex. Pediatrics. 2006;118(2):e488-e500. doi:10.1542/peds.2006-0738.
11.
LeePAHoukCP. Disorders of sexual differentiation in the adolescent. Ann N Y Acad Sci. 2008;1135:67-75. doi:10.1196/annals.1429.028.
12.
CastroCCGuaragna-FilhoGCalaisFL, et al. Clinical and molecular spectrum of patients with 17β-hydroxysteroid dehydrogenase type 3 (17-β-HSD3) deficiency. Arq Bras Endocrinol Metabol. 2012;56(8):533-539. doi:10.1590/s0004-27302012000800012.
13.
GeisslerWMDavisDLWuL, et al. Male pseudohermaphroditism caused by mutations of testicular 17 beta-hydroxysteroid dehydrogenase 3. Nat Genet. 1994;7(1):34-39. doi:10.1038/ng0594-34.
14.
YangZYeLWangW, et al. 17β-Hydroxysteroid dehydrogenase 3 deficiency: three case reports and a systematic review. J Steroid Biochem Mol Biol. 2017;174:141-145. doi:10.1016/j.jsbmb.2017.08.012.
15.
Cohen-KettenisPT. Gender change in 46,XY persons with 5alpha-reductase-2 deficiency and 17beta-hydroxysteroid dehydrogenase-3 deficiency. Arch Sex Behav. 2005;34(4):399-410. doi:10.1007/s10508-005-4339-4.
